Novo Nordisk's reimbursement appeal goes unheard, Sanofi insulin deemed equivalent

The Danish Medicines Agency's Reimbursement Committee has decided to ignore Novo Nordisk's pleas to leave the company's general reimbursement scheme untouched. Instead, it recommends other fast-acting insulins for new patients.

A trip to the pharmacy for users of Novo Nordisk's Fiasp could become more expense going forward. The Danish Medicines Agency's Reimbursement Committee has recommended a adjusting the fast-acting insulin's reimbursement scheme for the worse.

The Danish Medicines Agency has received the Reimbursement Committee's final recommendation for a revision pertaining to the reimbursement scheme for insulin products – and it doesn't bode well for Novo Nordisk.

Attempts to convince the committee to change their minds have fallen short. At the beginning of November, the Danish pharmaceutical firm objected to the change to reimbursements, which would see Novo Nordisk's fast-acting insulin Fiasp receive conditional reimbursement as opposed to a general reimbursement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs